Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Buy
51
RGR Quote, Financials, Valuation and Earnings
Last price:
$39.39
Seasonality move
:
5.63%
Day range:
$39.70 - $40.14
52-week range:
$34.11 - $48.20
Dividend yield:
1.75%
P/E ratio:
22.56x
P/S ratio:
1.29x
P/B ratio:
2.09x
Volume:
138.2K
Avg. volume:
158K
1-year change:
-13.63%
Market cap:
$669.3M
Revenue:
$535.6M
EPS (TTM):
$1.77
Analysts' Opinion
-
Consensus RatingSturm Ruger & has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $46.00, Sturm Ruger & has an estimated upside of 15.2% from its current price of $39.93.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $46.00 representing 100% downside risk from its current price of $39.93.
Fair Value
-
According to the consensus of 1 analyst, Sturm Ruger & has 15.2% upside to fair value with a price target of $46.00 per share.
RGR vs. S&P 500
-
Over the past 5 trading days, Sturm Ruger & has overperformed the S&P 500 by 0.45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sturm Ruger & does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sturm Ruger & has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Sturm Ruger & reported revenues of $145.8M.
Earnings Growth
-
Sturm Ruger & has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sturm Ruger & reported earnings per share of $0.62.
Enterprise value:
563.8M
EV / Invested capital:
1.76x
Price / LTM sales:
1.29x
EV / EBIT:
14.89x
EV / Revenue:
1.05x
PEG ratio (5yr expected):
--
EV / Free cash flow:
16.26x
Price / Operating cash flow:
19.90x
Enterprise value / EBITDA:
9.41x
Gross Profit (TTM):
$114.4M
Return On Assets:
7.97%
Net Income Margin (TTM):
5.71%
Return On Equity:
9.44%
Return On Invested Capital:
9.44%
Operating Margin:
7.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $595.8M | $543.8M | $535.6M | $130.6M | $145.8M | |
| Gross Profit | $180.1M | $133.6M | $114.4M | $32.3M | $33.2M | |
| Operating Income | $103.4M | $52.1M | $31.7M | $10.3M | $11.4M | |
| EBITDA | $134.3M | $81.4M | $59.9M | $14.8M | $18.2M | |
| Diluted EPS | $4.96 | $2.72 | $1.77 | $0.58 | $0.62 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $234.4M | $328.7M | $361.8M | $271.4M | $258.4M | |
| Total Assets | $348.3M | $442.3M | $484.8M | $398.8M | $384M | |
| Current Liabilities | $81.8M | $77.1M | $163.1M | $63.2M | $60.8M | |
| Total Liabilities | $83.6M | $78.7M | $168M | $67.1M | $64.5M | |
| Total Equity | $264.7M | $363.7M | $316.7M | $331.7M | $319.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $77.2M | $33.9M | $55.5M | $16.6M | $20M | |
| Cash From Investing | $13.2M | $40.9M | -$13.8M | -$193K | -$10.6M | |
| Cash From Financing | -$46.3M | -$124.8M | -$46.9M | -$14.8M | -$6.9M | |
| Free Cash Flow | $49.5M | $18.1M | $34.7M | $12.4M | $16.4M | |
RGR
Sector
Market Cap
$669.3M
$412.6M
Price % of 52-Week High
82.84%
70.4%
Dividend Yield
1.75%
0%
Shareholder Yield
7.75%
3.85%
1-Year Price Total Return
-13.63%
-15%
Beta (5-Year)
0.145
0.943
Dividend yield:
1.75%
Annualized payout:
$0.69
Payout ratio:
38.7%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$39.71
200-day SMA
Buy
Level
$39.81
Bollinger Bands (100)
Buy
Level
35.49 - 39.69
Chaikin Money Flow
Buy
Level
14.1M
20-day SMA
Buy
Level
$39.75
Relative Strength Index (RSI14)
Buy
Level
58.20
ADX Line
Buy
Level
31.18
Williams %R
Neutral
Level
-50
50-day SMA
Buy
Level
$37.69
MACD (12, 26)
Buy
Level
0.53
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
22.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.4579)
Buy
CA Score
(Annual)
Level (2.033)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-3.2488)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
Stock Forecast FAQ
In the current month, RGR has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RGR average analyst price target in the past 3 months is $46.00.
-
Where Will Sturm Ruger & Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sturm Ruger & share price will rise to $46.00 per share over the next 12 months.
-
What Do Analysts Say About Sturm Ruger &?
Analysts are divided on their view about Sturm Ruger & share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sturm Ruger & is a Sell and believe this share price will drop from its current level to $46.00.
-
What Is Sturm Ruger &'s Price Target?
The price target for Sturm Ruger & over the next 1-year time period is forecast to be $46.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RGR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sturm Ruger & is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of RGR?
You can purchase shares of Sturm Ruger & via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sturm Ruger & shares.
-
What Is The Sturm Ruger & Share Price Today?
Sturm Ruger & was last trading at $39.39 per share. This represents the most recent stock quote for Sturm Ruger &. Yesterday, Sturm Ruger & closed at $39.93 per share.
-
How To Buy Sturm Ruger & Stock Online?
In order to purchase Sturm Ruger & stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Signet Jewelers Stock Go Up So Much?
Signet Jewelers (NYSE:SIG) is the largest diamond retailer in the…
Why Did HealthEquity Stock Fall So Much?
HealthEquity (NASDAQ:HQY) is a fintech company that acts as an…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
69
CNXC alert for Mar 28
Concentrix [CNXC] is down 12.39% over the past day.
Buy
74
SLNO alert for Mar 28
Soleno Therapeutics [SLNO] is up 6.8% over the past day.
Buy
51
CAR alert for Mar 28
Avis Budget Group [CAR] is up 0.71% over the past day.
